AU2010317883B2 - Tricyclic pyrazol amine derivatives - Google Patents

Tricyclic pyrazol amine derivatives Download PDF

Info

Publication number
AU2010317883B2
AU2010317883B2 AU2010317883A AU2010317883A AU2010317883B2 AU 2010317883 B2 AU2010317883 B2 AU 2010317883B2 AU 2010317883 A AU2010317883 A AU 2010317883A AU 2010317883 A AU2010317883 A AU 2010317883A AU 2010317883 B2 AU2010317883 B2 AU 2010317883B2
Authority
AU
Australia
Prior art keywords
pct
denotes
het
formula
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010317883A
Other languages
English (en)
Other versions
AU2010317883A1 (en
Inventor
Pascale Gaillard
Isabelle Jeanclaude-Etter
Seenisamy Jeyaprakashnarayanan
Mathilde Muzerelle
Vincent Pomel
Eric Sebille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of AU2010317883A1 publication Critical patent/AU2010317883A1/en
Application granted granted Critical
Publication of AU2010317883B2 publication Critical patent/AU2010317883B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
AU2010317883A 2009-11-13 2010-11-12 Tricyclic pyrazol amine derivatives Active AU2010317883B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09175933 2009-11-13
EP09175933.2 2009-11-13
US26185409P 2009-11-17 2009-11-17
US61/261,854 2009-11-17
PCT/EP2010/067412 WO2011058149A1 (en) 2009-11-13 2010-11-12 Tricyclic pyrazol amine derivatives

Publications (2)

Publication Number Publication Date
AU2010317883A1 AU2010317883A1 (en) 2012-05-03
AU2010317883B2 true AU2010317883B2 (en) 2015-08-06

Family

ID=41796476

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010317883A Active AU2010317883B2 (en) 2009-11-13 2010-11-12 Tricyclic pyrazol amine derivatives

Country Status (14)

Country Link
US (1) US9073940B2 (enExample)
EP (1) EP2499146B1 (enExample)
JP (1) JP5735526B2 (enExample)
KR (1) KR20130049766A (enExample)
CN (1) CN102695710B (enExample)
AR (1) AR078979A1 (enExample)
AU (1) AU2010317883B2 (enExample)
CA (1) CA2778174C (enExample)
EA (1) EA201290305A1 (enExample)
ES (1) ES2607952T3 (enExample)
IL (1) IL219602A (enExample)
MX (1) MX2012005518A (enExample)
WO (1) WO2011058149A1 (enExample)
ZA (1) ZA201202641B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044451B2 (en) 2010-07-19 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
JP6367211B2 (ja) * 2012-11-16 2018-08-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体
WO2014121901A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
RU2663898C2 (ru) * 2013-06-24 2018-08-13 Мерк Патент Гмбх Пиразольные соединения в качестве модуляторов fshr и их применение
WO2015196335A1 (en) * 2014-06-23 2015-12-30 Tocopherx, Inc. Pyrazole compounds as modulators of fshr and uses thereof
AU2016313263B2 (en) 2015-08-26 2021-02-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Condensed tricyclic compounds as protein kinase inhibitors
TW201837026A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（二）
KR102515694B1 (ko) 2017-01-10 2023-03-29 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
CN108434150B (zh) * 2018-02-09 2020-03-10 天津医科大学总医院 Zstk474用于制备ean治疗药物的应用
EP3608326A1 (en) * 2018-08-10 2020-02-12 Irbm S.P.A. Tricyclic inhibitors of hepatitis b virus
CN113754678B (zh) * 2020-06-02 2023-03-10 江苏恒瑞医药股份有限公司 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用
CN113754685B (zh) * 2020-06-02 2023-06-16 江苏恒瑞医药股份有限公司 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用
BR112022026904A2 (pt) 2020-07-02 2023-01-24 Bayer Ag Derivados de heterocicleno como agentes de controle de pragas
WO2022007924A1 (zh) * 2020-07-09 2022-01-13 江苏恒瑞医药股份有限公司 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用
WO2022022630A1 (zh) 2020-07-29 2022-02-03 江苏恒瑞医药股份有限公司 氧杂氮杂螺环类衍生物、其制备方法及其在医药上的应用
GB202117511D0 (en) * 2021-12-03 2022-01-19 Ionctura Sa Treatment regimens
FI4313058T3 (fi) * 2021-03-29 2025-04-30 Ionctura Sa Roginolisibia käsittävä koostumus ja annosteluohjelma syövän tai tulehdus- tai autoimmunisairauden hoitoon
JP2024511836A (ja) * 2021-03-29 2024-03-15 アイオンクチュラ・ソシエテ・アノニム 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤
CN114524827B (zh) * 2022-02-22 2024-07-09 深圳市儿童医院 一种用于治疗神经重症的吡唑衍生物及其应用
CN114524828B (zh) * 2022-02-22 2024-07-09 深圳市儿童医院 一种用于治疗神经重症的噻唑衍生物及其应用
CN115491252B (zh) * 2022-09-29 2023-05-02 江苏四新界面剂科技有限公司 一种宝石切割用低泡润湿剂及其制备方法
WO2024184266A1 (en) 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
JP2026510567A (ja) 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ
GB202308807D0 (en) 2023-06-13 2023-07-26 Ionctura Sa Combinations
AU2024357109A1 (en) 2023-10-06 2026-03-12 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor
WO2025195504A1 (zh) * 2024-03-22 2025-09-25 复旦大学附属中山医院 三环骨架化合物及其在制备抗肿瘤药物中的应用
TWI926701B (zh) * 2024-03-22 2026-05-21 復旦大學附屬中山醫院 三環骨架化合物及其在製備抗腫瘤藥物的應用
GB202418087D0 (en) 2024-12-10 2025-01-22 Ionctura Sa Biomarkers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056820A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816467A (en) 1987-01-09 1989-03-28 Farmitalia Carlo Erba S.R.L Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use
GB8814586D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Tricyclic 3-oxo-propanenitrile derivatives & process for their preparation
GB8907799D0 (en) * 1989-04-06 1989-05-17 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
GB8916290D0 (en) * 1989-07-17 1989-08-31 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in stimulating myelopoiesis
JP3542826B2 (ja) 1994-07-11 2004-07-14 帝国臓器製薬株式会社 新規な二環式化合物縮合［２，１−ｄ］イソキサゾール−３−カルボン酸誘導体
GB9720901D0 (en) * 1997-10-01 1997-12-03 Pharmacia & Upjohn Spa Condensed benzothiopyranic compounds
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
MXPA05000453A (es) 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
US7691888B2 (en) 2004-10-07 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole
CA2633500A1 (en) 2005-12-20 2007-07-05 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
WO2008035356A2 (en) 2006-09-20 2008-03-27 Glenmark Pharmaceuticals Limited Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2009010824A1 (en) 2007-07-13 2009-01-22 Glenmark Pharmaceuticals, S.A. Dihydrochromenopyrazole derivatives as vanilloid receptor ligands
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056820A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1189973-87-2 *
CAS Registry Number 931355-99-6 *
CAS Registry Number 931714-28-2 *

Also Published As

Publication number Publication date
CA2778174C (en) 2018-02-20
US9073940B2 (en) 2015-07-07
JP5735526B2 (ja) 2015-06-17
CA2778174A1 (en) 2011-05-19
AR078979A1 (es) 2011-12-14
ZA201202641B (en) 2013-06-26
EA201290305A1 (ru) 2012-12-28
EP2499146A1 (en) 2012-09-19
JP2013510825A (ja) 2013-03-28
ES2607952T3 (es) 2017-04-04
US20120238545A1 (en) 2012-09-20
AU2010317883A1 (en) 2012-05-03
IL219602A0 (en) 2012-07-31
KR20130049766A (ko) 2013-05-14
EP2499146B1 (en) 2016-09-21
CN102695710A (zh) 2012-09-26
WO2011058149A1 (en) 2011-05-19
MX2012005518A (es) 2012-06-19
CN102695710B (zh) 2015-08-19
IL219602A (en) 2017-04-30

Similar Documents

Publication Publication Date Title
EP2499146B1 (en) Tricyclic pyrazol amine derivatives
EP2872501B1 (en) Pyrimidine pyrazolyl derivatives
US9957281B2 (en) Benzodiazepine derivatives as RSV inhibitors
JP6479476B2 (ja) ＳｙｋチロシンキナーゼインヒビターおよびＧＣＮ２セリンキナーゼインヒビターとしての８−置換２−アミノー［１，２，４］トリアゾロ［１，５−Ａ］ピラジン類
US20110257170A1 (en) 4-morpholino-pyrido[3,2-d]pyrimidines
CA3077309A1 (en) Combination pharmaceutical agents as rsv inhibitors
CA2992408A1 (en) Substituted aza compounds as irak-4 inhibitors
WO2009133127A1 (en) Fused bicyclic compounds and use thereof as pi3k inhibitors
US20260062416A1 (en) Inhibitors of kif18a and uses thereof
AU2011347711A1 (en) Indazolyl triazole derivatives as IRAK inhibitors
SG185515A1 (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
CA2925624A1 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
WO2020116662A1 (ja) シクロアルカン−１，３−ジアミン誘導体
US20230265103A1 (en) Novel inhibitors of pikfyve and methods using same
EP2396322B9 (en) 2-Morpholino-pyrido[3,2-d]pyrimidines
EP4694893A1 (en) Novel inhibitors of pikfyve and methods using same
HK1171742A (en) Tricyclic pyrazol amine derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)